Article
Engineered AAV9 as <i>in vivo</i> gene delivery platform for the selective transduction of TME cell subsets
2025-06-14
Abstract excerpt
Precise in vivo gene delivery to specific cell types remains a significant challenge in gene therapy, particularly for cancer immunotherapy applications. Here, we rationally engineered AAV9 to become a modular, receptor-targeted vector for selective in vivo gene delivery. We first identified the N272A and W503A mutations as effective in ablating the native tropism of AAV9. Subsequently, designed ankyrin repeat p...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 10f0935b-5b5b-521f-93e3-37398f8e6d51
- DOI
- 10.1101/2025.06.11.658408
